Trigeminal Neuralgia Treatment Medicine Market Analysis, Overview, Growth, Demand and Forecast Research Report to 2026

The MarketWatch News Department was not involved in the creation of this content.

Nov 25, 2020 (The Expresswire) —
The report “Trigeminal Neuralgia Treatment Medicine Market” in Global to 2026 – Market Scope, Development, and Predictions offers the most up-to-date industry information on the actual market situation, and future outlook for vision frames and mountings in worldwide.

The research includes historic data from 2020 and forecasts until 2026 which makes the report a valuable resource for industry executives, presentation, sales and product managers, consultants, analysts, and other people looking for key industry data in a readily available document with clearly presented tables and Figures.

Request a sample copy of the report – https://www.absolutereports.com/enquiry/request-sample/16562110

Trigeminal Neuralgia Treatment Medicine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Trigeminal Neuralgia Treatment Medicine business, the date to enter into the Trigeminal Neuralgia Treatment Medicine market, Trigeminal Neuralgia Treatment Medicine product introduction, recent developments, etc.

The Following Manufacturers Are Covered in This Report:

● Novartis Pharma AG ● Sihuan Pharma ● Wuhan Humanwell ● Raybow Pharma ● Jinan Jinda Pharmaceutical ● Sinopharm ● Jiangsu Tohope Pharma ● Yabang Medicine ● Taro ● Torrent Pharmas ● Wockhardt Bio AG ● Apotex Inc ● Teva Pharmas ● Zydus Pharms ● Unique Pharm ● Rubicon ● Sun Pharma Inds ● Glenmark Pharms Ltd ● Breckenride Pharm ● Amneal Pharms

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT – REQUEST SAMPLE

Trigeminal Neuralgia Treatment Medicine Market Breakdown Data by Type

● Carbamazepine ● Oxcarbazepine ● Others

Trigeminal Neuralgia Treatment Medicine Market Data by Application

● Hospitals ● Clinic ● Others

Inquire Or Share Your Questions If Any Before The Purchasing This Report – https://www.absolutereports.com/enquiry/pre-order-enquiry/16562110

Geographic Segmentation

The report offers exhaustive assessment of different region-wise and country-wise Breast Localization Needles markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. Key regions covered in the report are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Breast Localization Needles market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.

Detailed TOC of Global Trigeminal Neuralgia Treatment Medicine Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application

1 Trigeminal Neuralgia Treatment Medicine Market Overview

1.1 Product Overview and Scope of Trigeminal Neuralgia Treatment Medicine

1.2 Trigeminal Neuralgia Treatment Medicine Segment by Type

1.2.1 Global Trigeminal Neuralgia

Read more

Can I go to the dentist in lockdown? Here’s how new restrictions effect treatment

A fresh lockdown coming into force within days will have left many frantically cancelling appointments.

But a date with the dentist is a vital service – and many will be concerned they will lose their appointments as businesses are forced to shut down once again.

Dentists were closed to all but emergency appointments during the early stages of the first lockdown. 

But there will be different rules in place for the second national lockdown, which comes into force from Thursday, October 5, until at least Wednesday, December 2.

People will be allowed to leave their homes for medical appointments

Dentists will remain open during the fresh coronavirus lockdown that kicks in on Thursday, it has been confirmed.

They will remain open for appointments, including regular check-ups during England’s second major shut-down.

Businesses including non-essential shops will be forced to closed once again in the government’s latest bid to curb spread of Covid-19.

But the British Association of Private Dentistry assured dental practices were considered essential.

The association tweeted: “Despite an impending lockdown private practices will remain OPEN.

“It’s safe and essential to attend the dentist.

“We remain open to all, for both routine and emergency treatments. #DentalCare”.

One of the reasons people are permitted to leave their home is for “medical reasons, appointments or to escape injury”.


Boris Johnson urged people to continue to use the NHS for treatment during his speech on Saturday, in which he outlined the new rules.

He said: “So please – this is really important – unless your clinicians tell you otherwise, you should continue to use the NHS, get your scans, turn up for your appointments and pick up your treatments.

“If at all possible, we want you to continue to access these services, now and through the winter.

“Indeed it’s only by taking this action that we can protect the NHS for you.”

Under the new rules, people are allowed to leave the house for a limited number of reasons.

There will be no time limit on how long people can go out for exercise.

People can also go outdoors for recreation with their own household, or on their own with one person from another household.

People will not be allowed to meet in homes and gardens, except for with members of their household ‘bubble’.

People can also leave home to shop for food and essentials and to provide care for vulnerable people or volunteering work.

Overnight stays outside of the home will only be allowed for work purposes, the new rules state.

Click here for a list of reasons you are allowed to leave the house under the new coronavirus lockdown rules.

Read more

European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

  • Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer

  • Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care

Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re delighted that people in Europe can now benefit from this combination and we look forward to working with individual countries within the EU to ensure people can access the combination as soon as possible.”

“The results of the IMbrave150 study mark a breakthrough in the treatment of advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Dr Arndt Vogel, Professor of Medicine at Hannover Medical School. “After many failures in the last 12 years, the combination of Tecentriq and Avastin shows improvement in overall survival compared to sorafenib and offers patients the opportunity for improved disease control with a high overall response rate.”

The approval is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of death (overall survival [OS]) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; p=0.0006) and reduced the risk of disease worsening or death (progression-free survival [PFS]) by 41% (HR=0.59; 95% CI: 0.47–0.76; p<0.0001), compared with sorafenib. IMbrave150 is the first Phase III cancer immunotherapy study to show an improvement in both OS and PFS in people with unresectable HCC compared with sorafenib. Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination (≥2%) were bleeding in the gastrointestinal tract and fever. These results were published in the New England Journal of Medicine on 14 May 2020.

Today’s approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2020. In May 2020, the US Food and Drug Administration approved Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy. In addition, in October 2020 the China National Medical Products Administration approved the combination for the treatment of people with unresectable HCC who have not received prior systemic therapy. In total, the combination is now approved in 59 countries for people with unresectable HCC. Tecentriq in combination with Avastin was also recently included as

Read more

Does Medicare cover leukemia care? Treatment, costs and options

There are benefits included in Medicare plans that can help with treatment costs relating to leukemia. Out-of-pocket expenses may apply, but there may be additional support available.

Medicare covers many of the costs of care relating to leukemia. As with other cancer, doctors customize treatment options for people based on their medical history and type of cancer.

In this article, we discuss the different treatments for leukemia, what Medicare covers, and other options that may be available.

We may use a few terms in this piece that can be helpful to understand when selecting the best insurance plan:

  • Deductible: This is an annual amount that a person must spend out of pocket within a certain time period before an insurer starts to fund their treatments.
  • Coinsurance: This is a percentage of a treatment cost that a person will need to self-fund. For Medicare Part B, this comes to 20%.
  • Copayment: This is a fixed dollar amount that an insured person pays when receiving certain treatments. For Medicare, this usually applies to prescription drugs.

Original Medicare has two parts that each provide coverage for care received in different settings.

Medicare Part A

Medicare Part A is sometimes called hospital insurance and covers inpatient hospital stays, including cancer treatment a person receives while in the hospital.

Part A also pays for skilled nursing facilities, hospice, and home healthcare. Home healthcare can include:

  • physical therapy
  • speech and language therapy
  • occupational therapy
  • skilled nursing care

A person enrolled in an eligible clinical research study may also have some costs covered by Part A.

Medicare Part B

Medicare Part B is sometimes called medical insurance. This part of Medicare pays for medically necessary, cancer-related treatments and services a person may need outside the hospital.

This can include:

  • doctor visits
  • chemotherapy drugs administered intravenously in an outpatient clinic or doctor’s office
  • some oral chemotherapy
  • durable medical equipment (DME) like wheelchairs or walkers
  • mental health services
  • nutritional counseling
  • radiation treatment

In some instances, Medicare Part B will cover the cost of a second opinion for surgery. This happens if the surgery is not an emergency. They may cover a third opinion if the first and second opinions differ.

Medicare Part D

Medicare Part D, also known as a prescription drug plan (PDP), covers outpatient prescription drugs. Private insurance companies administer these plans.

Some chemotherapy drugs that are not covered by Part B, may be covered under a PDP, as well as prescribed pain relief and anti-emetics.

Surgical options

Surgery plays a limited role in treating leukemia since blood carries the disease throughout the body.

An individual may get a central venous catheter, which is a flexible tube that is inserted into a large vein, making it easier to administer chemotherapy. This is an inpatient surgical procedure that is covered by Part A.

A person may also have a biopsy of the lymph nodes or bone marrow that can help diagnose leukemia. The biopsy is an outpatient procedure and is covered by Part B.

The body has several

Read more

Congressman Calls For Federal Crackdown On Unproven Coronavirus Treatment : Coronavirus Updates : NPR

Congressman Raja Krishnamoorthi, an Illinois Democrat, is calling on the Food and Drug Administration and the Federal Trade Commission to investigate sales of a non-FDA approved drug marketed as a treatment for COVID-19.

Tom Williams/AFP via Getty Images


hide caption

toggle caption

Tom Williams/AFP via Getty Images

Congressman Raja Krishnamoorthi, an Illinois Democrat, is calling on the Food and Drug Administration and the Federal Trade Commission to investigate sales of a non-FDA approved drug marketed as a treatment for COVID-19.

Tom Williams/AFP via Getty Images

A member of Congress, who has led efforts to investigate alleged coronavirus scams, is calling for the federal government to crack down on an unproven treatment for COVID-19. Widespread sales of that purported treatment – a drug known as thymosin alpha-1 – were first identified by an NPR investigation earlier this month. More than 30 doctors in more than a dozen states around the country have marketed the drug as a treatment for the coronavirus, despite the fact that it has never been approved by the Food and Drug Administration for any condition and such claims are, in the words of the FDA, “not supported by competent and reliable scientific evidence.”

The congressman, Rep. Raja Krishnamoorthi (D-Ill.), leads the House Subcommittee on Economic and Consumer Policy. He is now calling for the FDA and the Federal Trade Commission to take action against one prominent doctor who has marketed the drug: Dr. Dominique Fradin-Read of Los Angeles.

Fradin-Read is known for her work with the actor Gwyneth Paltrow’s wellness brand Goop. Fradin-Read helped formulate a dietary supplement called “Madame Ovary” for the brand. She also runs the practice VitaLifeMD, and had falsely marketed thymosin alpha-1 as an “FDA approved” drug, which she claimed was “one of the best ways to prevent and fight COVID-19.”

“Such false claims appear to be illegal and ought to be subject to strict enforcement by FDA and FTC,” Krishnamoorthi wrote in his letter to the leaders of those agencies. “I ask you to open an investigation into VitaLifeMD, and to take all appropriate action against VitaLifeMD and its principals.”

Fradin-Read did not respond to messages from NPR for this story. But she has previously defended prescriptions of the drug, saying she had prescribed it to members of her staff, her mother, and had even taken it herself without any negative effects.

The FTC and FDA are responsible for enforcing laws against false and misleading advertising. A spokesperson for the FTC declined to comment, and the FDA did not respond to a message NPR.

Earlier on in the pandemic, Krishnamoorthi called on the Trump Administration to take action against conspiracy theorist Alex Jones of InfoWars for marketing colloidal silver-infused toothpastes as a supposed COVID-19 prevention measure. (The National Institutes of Health say colloidal silver is not safe or effective for treating any condition, and can even permanently turn a person’s skin blue at high doses.) The FDA then warned Jones that such claims were misleading and could violate federal law.

Krishnamoorthi’s current

Read more

Rash around eyes: Causes, symptoms, and treatment

A rash can develop around the eyes for different reasons, including dermatological conditions and infections. Examples include atopic dermatitis, psoriasis, and cellulitis.

Doctors may find it difficult to diagnose skin problems around the eyes because many conditions may cause a rash. To diagnose a rash around the eyes, doctors require a detailed examination of the affected area and complete medical history.

Keep reading to learn more about the causes, symptoms, and treatment of a rash around the eyes.

Eczema is a chronic skin condition. Doctors have identified several different types of eczema, one example being atopic dermatitis (AD).

AD is a skin condition that usually appears in childhood and can develop on any area of the body, including the face and around the eyes.

The American Academy of Dermatology (AAD) state that researchers have identified the following factors that may play a role in causing AD:

People with AD may have an itchy rash. The AAD state that typically a person may first experience itchy skin. When a person scratches, a rash begins to appear.

The appearance of AD can vary depending on how old the person is:

In babies

In infants, the rash typically appears on the cheeks, scalp, and face. The skin may become dry or scaly. Sometimes, the rash may form blisters and then ooze and weep fluid.

In children

Children may develop AD in the elbow and feet creases. Other locations include:

  • neck
  • wrists
  • ankles
  • crease between buttocks and legs

Some accompanying symptoms in children may include:

  • bumpy-looking skin
  • darkened or lightened skin around the area of the rash
  • thickened or leathery skin

In adults

Approximately 2–3% of adults experience AD.

If it persists into adulthood, people may have fewer rashes. However, they tend to have:

  • extremely dry skin
  • skin that is easily irritated
  • hand eczema
  • eczema on the eyelids
  • cataracts

Adults with AD around the eyes may have darker, thickened skin circling the eyes, which may be very itchy.

Treatment

A person can make changes to their skin care routine and use certain medications to help treat AD.

Learn more about the treatment options for AD here.

Contact dermatitis is another type of eczema. There are two types of contact dermatitis:

Allergic contact dermatitis

Allergic contact dermatitis occurs when a person comes into contact with an allergen, such as:

  • nickel
  • latex
  • poison ivy
  • makeup

Symptoms include:

Irritant contact dermatitis

Irritant contact dermatitis occurs when a person comes into contact with something that damages the skin, such as:

Symptoms of irritant contact dermatitis include dry and chapped skin. If the exposure to the irritant continues, a person may notice inflamed, scaly, and swollen patches of skin.

Treatment

Treatment for either type of contact dermatitis may include antihistamines, moisturizers, and topical corticosteroid creams.

According to the British Association of Dermatologists, seborrheic means that the rash affects greasy skin zones. Seborrheic blepharitis affects the eyelids.

Seborrheic blepharitis typically occurs due to an overgrowth called Malassezia, which is a type of harmless yeast. It can also occur due

Read more

New Study Warns of Negative Impact COVID-19 is Having on Cancer Screenings, Diagnosis and Treatment

Co-Authored by Florida Cancer Specialists Oncologists Lucio Gordan, MD and Michael Diaz, MD, Study Predicts Significant Increase in Late-Stage Cancers and Potentially More Cancer Deaths

President &amp; Managing Physician Lucio Gordan, MD; Assistant Managing Physician Michael Diaz, MD
President & Managing Physician Lucio Gordan, MD; Assistant Managing Physician Michael Diaz, MD
President & Managing Physician Lucio Gordan, MD; Assistant Managing Physician Michael Diaz, MD

Fort Myers, Fla., Oct. 28, 2020 (GLOBE NEWSWIRE) — Lucio Gordan, MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and FCS Assistant Managing Physician Michael Diaz, MD are co-authors of a new national study that details the devastating effect the COVID-19 crisis has had on cancer screenings, diagnosis and treatment. Conducted for the Community Oncology Alliance (COA) by Avalere Health and in collaboration with Debra Patt, MD, PhD, MBA, FASCO, executive vice president, policy and strategic initiatives at Texas Oncology, the study is scheduled to be published in the November issue of the journal JCO Clinical Cancer Informatics. Its findings show a substantial decrease in the number of cancer screenings, diagnosis and treatment for senior adults and Medicare beneficiaries in 2020.

Gordan, Diaz and colleagues were part of the study’s research team of oncologists who reported that they are already seeing patients being diagnosed with later stage cancers, which require more complex treatment and often result in higher morbidity and mortality rates. “In the early months of the pandemic,” Dr. Gordan explained, “many people chose or had to delay or even skip regular screenings, such as mammograms, prostate exam, PSA testing or colonoscopies, among others, for various types of cancer. This has resulted in later diagnoses for some patients and delays in beginning treatment. Oncologists are preparing their practices for significant impact in cancer patient outcomes due to these delays.”

Dr. Diaz, who also serves as President of COA, concurs. “If cancers are not diagnosed at an early stage, we could face rising death rates for several years to come,” he said. “It is critical that adults with a family history of cancer and others who may be experiencing symptoms do not delay their screenings for the fear of being exposed to or contracting coronavirus. Medical practices now have numerous strategies in place to protect the safety and health of patients, doctors, nurses and other staff members.”

One positive revealed in the study was the rapid adoption of telehealth and other strategies by community oncology practices, such as Florida Cancer Specialists. Dr. Gordan said, “Community oncologists and their team members showed incredible resilience and resolve to deal with this severe crisis, by adopting telehealth very quickly, reorganizing workflows, enhancing safety processes at their clinics, and migrating staff to work from home, among other strategies. Although a decrease in services was inevitable, the resolve of these practitioners and staff handled and avoided what could have been a much worse situation.”

The study concludes that further analysis will be needed to evaluate the ongoing consequences of COVID-19 and its probable long-term impact on cancer care and outcomes.

The full study can be found online

Read more

First-Ever Treatment Shown to Reverse Alzheimer’s Earns NeuroEM Therapeutics FDA Breakthrough Device Status

The FDA is expediting a revolutionary clinical-stage head device to beat back Alzheimer’s disease at home

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005376/en/

Woman pictured wearing NeuroEM Therapeutics’ bioengineered MemorEM™ cap and arm control box. This revolutionary head device has earned FDA Breakthrough Device designation, having demonstrated in a pilot study that it can reverse Alzheimer’s disease. This woman’s participation in the study resulted in her regaining the equivalent of 12 months of memory. (Photo: Business Wire)

“No other drug or device has received this highest FDA designation to accelerate a treatment for Alzheimer’s disease,” said Dr. Robert Matthews, PhD, CEO of NeuroEM Therapeutics. “No other treatment has demonstrated the clinical results we have thus far, to not only slow but in fact reverse the progressive, debilitating loss of memory caused by this devastating brain disease.”

The FDA has given Breakthrough status to over 300 devices and over 100 drugs, but none to a therapeutic for Alzheimer’s disease – until now. NeuroEM’s head device (MemorEMTM) is the first-ever Alzheimer’s treatment (device or drug) to receive FDA Breakthrough status. The FDA program is designed to expedite the development and review process of new technology for patients with life-threatening or irreversibly debilitating conditions, such as Alzheimer’s Disease.

  • NeuroEM’s novel, proprietary technology, called Transcranial Electromagnetic Treatment (TEMT), achieves what other treatments for AD have not. In fact, no other therapy comes close to MemorEM’s remarkable results, made possible by its unique modes of action.

  • In just two months of daily use, the MemorEM restored on average the equivalent of 12 months of memory for 7 of 8 participants in its pilot study, none of whom experienced adverse side effects.

  • Treatment is easy, comfortable and safe. A patient wears what appears to be a simple cap that belies the complex biomedical engineering within it. The device is worn twice a day in home for an hour at a time, and its design allows the patient to move around home as usual.

NeuroEM has pioneered TEMT to successfully penetrate the skull to reach vital nerve cells in the brain called neurons. NeuroEM’s revolutionary TEMT technology works by breaking up small aggregates (oligomers) of two toxic proteins, called β-amyloid and tau, that are made inside the brain’s neurons during the Alzheimer’s disease process. These two toxic oligomers appear to be the root cause of Alzheimer’s disease by wreaking havoc on vital functions within neurons – especially in brain areas involved in memory. The electromagnetic waves emanating from multiple emitters within NeuroEM’s MemorEM head device easily penetrate the human brain and gently disassociate the toxic oligomers inside neurons resulting in a reversal of Alzheimer’s memory impairment in key

Read more

The Biggest Difference Between a Vaccine and a Treatment

Photo credit: Anadolu Agency - Getty Images
Photo credit: Anadolu Agency – Getty Images

From Men’s Health

As the coronavirus continues to shake the country without proven medications to fight the novel disease, doctors and scientists are racing for a breakthrough in developing both vaccines and treatments.

But as dozens of COVID-19 vaccines enter advanced clinical trial stages and the FDA approves possible treatment drugs (such as Remdesivir) and continues to review others, we’ve noticed that there’s confusion around what a vaccine does and what a treatment does.

The biggest difference between a vaccine and a treatment is that one is designed to prevent, while the other is designed to treat or cure. Both, however, would be beneficial when it comes to preventing and managing COVID-19.

Vaccines: What they are and what they do

A vaccine is a product that stimulates the immune system to produce immunity to a specific disease without you ever having to get the disease first, according to the Centers for Disease Control and Prevention. For example, the flu shot is a vaccination that works to prevent a person from getting sick from influenza by rallying the immune system against the viruses that cause the flu.

Photo credit: Men's Health
Photo credit: Men’s Health

Treatments: What they are and what they do

Treatments, on the other hand, come into play after an individual is already sick. They work to help those that are sick survive and recover.

Dr. Davey Smith, head of the Division of Infectious Disease and Global Health at UC San Diego, says that while vaccines for COVID-19 are important, treatments are still crucial. “The FDA said they will approve a coronavirus that works 50 percent of the time,” he explains. “I still have a 50% chance of getting sick. And I really need to have a [treatment] that’s going to keep me from getting sicker and perhaps dying.”

Ultimately, establishing both vaccines and treatments during the pandemic is vital as COVID-19 continues to spread.

You Might Also Like

Source Article

Read more

This Addiction Treatment Works. Why Is It So Underused?

“In the drawings, I did pretty good,” said Eric Alick, 63, of Philadelphia, who completed a contingency management program for cocaine addition at the Corporal Michael J. Crescenz V.A. Medical Center in Pennsylvania. “I might get three ‘good jobs’ in a row, but then, bingo.”

Among the things he bought with his rewards were a new drill set for his job as a handyman, perfume for his wife and coffee and meals for homeless veterans whom he had met in the hospital cafeteria.

One problem with contingency management, evidence suggests, is that people have less success staying abstinent after the treatment ends. For that reason, Richard Rawson, a researcher at the University of Vermont who has studied meth addiction for decades, believes it should be used indefinitely, just as medications for opioid addiction often are.

“Unfortunately, addiction is a chronic brain disease and treatments need to be designed to accommodate this reality,” he said.

For Ms. Waxler-Malloy, losing the debit card when her four months of contingency management ended in early January was hard, although her therapy sessions and 12-step meetings helped. Then, in May, she lost her waitressing job because of the pandemic and she relapsed, using meth and heroin “full force,” she said, for three weeks before stopping with help from Brightview.

Still, the eight months she went without using drugs was her longest stretch of abstinence in more than two decades. She believes she may not have relapsed if contingency management, with its promise of rewards, had still been part of her treatment regimen.

“That kept me real accountable,” she said recently. “Even just to stop at McDonald’s when you have that little bit of extra money, to get a hamburger and a fries when you’re hungry. That was really big to me.”

Source Article

Read more